News

Article

NextPharma Acquires Chewable Tablets Manufacturing Site in Norway

Author(s):

NextPharma has acquired a leading European chewable tablets manufacturing site from Takeda in Asker, Norway.

NextPharma, a European contract development and manufacturing organization (CDMO), announced on April 1, 2023 that it has acquired a leading chewable tablets manufacturing site from Takeda located in Asker, Norway.

The site, which has approximately 170 employees, has operated for more than 50 years and produces a broad portfolio of strengths and flavors of calcium/vitamin D3 chewable tablets. The site will be NextPharma’s center of excellence for the development and manufacturing of chewable tablet forms, adding to the company’s existing site portfolio.

“With NextPharma, we are confident that Takeda has chosen a buyer who will help nurture and grow the Asker site,” said Bjørn Lie, head of the manufacturing site at Asker, in a company press release. “We are all excited about joining the NextPharma team and look forward to working together to drive the long-term development and growth of the business and our people.”

“We are excited by the addition of a world-class manufacturing site and a new center of excellence for chewable tablets to our operational network, allowing us to further broaden our technology offering for both existing and new customers,” added Peter Burema, CEO of NextPharma, in the release. “These technologies, combined with the know-how and expertise of the site’s employees, will continue to benefit patients across the world.”
Source: NextPharma

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content